Fibroblastic growth factor 23 (FGF23) is a circulating hormone mainly secreted by
the osteocytes in the bone. Around 2000, after decades of research, FGF23 was discovered
as being the “circulating factor phosphatonin” that causes the symptoms in patients
with autosomal dominant hypophosphatemic rickets (ADHR). This disease is characterized
by hypophosphatemia and hypophosphaturia resulting in growth retardation, bone deformities
and rickets. Patients with ADHR develop flares of hypophosphatemia that coincidence
with the development of iron deficiency and thus microcytic anemia [
1
,
2
]. This finding has led to studies that elucidated the role of FGF23 in the calcium
phosphate balance and subsequential research that untangled the interactions between
iron balance, erythropoiesis and FGF23. There is a remarkable similarity between the
systemic effects of blood donation on the calcium phosphate balance and iron state
on the one side and the stimuli that have been found to induce an increase in FGF23
levels on the other.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Iron deficiency drives an autosomal dominant hypophosphatemic rickets and healthy humans.PNAS. 2011; 108: 1146-1155
- Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.J Clin Endocrinol Metab. 2011; 96: 3541-3549
- FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.Nat Rev Nephrol. 2020; 16: 7-19
- Regulation of erythropoiesis by hypoxia-inducible factors.Blood Rev. 2013; 27: 41-53
- Crosstalk between FGF23, iron, erythropoietin and inflammation in kidney disease.Curr Opin Nephrol Hypertens. 2019; 28: 304-310
- Renal and extrarenal effects of fibroblast growth factor 23.Nat Rev Nephrol. 2019; 15: 109-120
- Donation-induced iron depletion is significantly associated with low hemoglobin at subsequent donations.Transfusion. 2021; 61: 3344-3352
- Evidence of relative iron deficiency in platelet- and plasma-pheresis donors correlates with donation frequency.J Clin Apher. 2016; 31: 551-558
- Apheresis affects bone and mineral metabolism.Bone. 2010; 46: 789-795
Article info
Publication history
Published online: February 24, 2023
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Published by Elsevier Ltd.
